The value of pre-transplant factors for predicting the development of cardiac complications after transplantation has been inconsistent among studies. We analyzed the impact of pre-transplant factors on the incidence of severe cardiac complications in 164 hematopoietic stem cell transplant recipients. We identified eight patients (4.8%) who experienced grade III or IV cardiac complications according to the Bearman criteria. Seven died of cardiac causes a median of 3 days after the onset of cardiac complications. On univariate analysis, both the cumulative dose of anthracyclines and the use of anthracyclines within 60 days before transplantation affected the incidence of severe cardiac complications (P ¼ 0.0091 and 0.011). The dissociation of heart rate and body temperature, which reflects 'relative tachycardia', was also associated with a higher incidence of cardiac complications (P ¼ 0.024). None of the variables obtained by electrocardiography or echocardiography were useful for predicting cardiac complications after transplantation, although the statistical power might not be sufficient to detect the usefulness of ejection fraction. On a multivariate analysis, the cumulative dose of anthracyclines was the only independent significant risk factor for severe cardiac complications. We conclude that the cumulative dose of anthracyclines is the most potent predictor of cardiac complications and the administration of anthracyclines should be avoided within two months before transplantation. anthracycline; ejection fraction Cardiac complications due to conditioning regimens are well recognized, and these include congestive heart failure, fatal arrhythmia, and cardiac tamponade. The incidence of such complications has varied among studies, from less than 1% to more than 26%.
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Patients and methods

Patients
Of the 207 adult patients who underwent hematopoietic stem cell transplantation for the first time between June 1995 and March 2003 at the University of Tokyo Hospital, Japan, we retrospectively reviewed the records of 164 patients for whom a standard 12-lead ECG and UCG within 3 months before transplantation was available. Patient characteristics are shown in Table 1 . Acute leukemia in first or second remission, chronic myeloid leukemia in chronic phase, myelodysplastic syndrome with refractory anemia or refractory anemia with ringed sideroblasts, lymphoma or solid cancers in remission, and severe aplastic anemia were defined as standard-risk diseases, while others were considered high-risk diseases. In all, 132 patients underwent allogeneic transplantation, while 31 and one underwent autologous and syngeneic transplantation, respectively. Cyclophosphamide at more than 100 mg/kg was used in 129 patients (79.9%) and ifosfamide at 12 g/m 2 was used in one patient (0.6%). Total body irradiation was applied in 89 patients (54.2%).
Evaluation of pre-transplant factors
QT intervals were measured manually from the beginning of the QRS complex to the end of the T wave. The average of two consecutive QT intervals was calculated as the QT interval for each lead and the QT interval for each patient was calculated as the mean QT interval of all available leads. QT dispersion was defined as the difference between the longest and shortest QT interval. Each value was corrected with Bazett's formula. QT dispersion could not be determined in three patients either because there were fewer than six readable leads (n ¼ 2) or due to frequent premature ventricular contractions (n ¼ 1).
Left ventricular EF and the E/A mitral Doppler ratio were evaluated by UCG as indices of systolic and diastolic functions, respectively. The cutoff of EF was determined as 55%, because the best P-value was obtained at this cutoff by univariate analyses. The following variables were also evaluated: left atrial dimension (LAD), left ventricular enddiastolic dimension (LVDd), left ventricular end-systolic dimension (LVDs), end-diastolic intraventricular septal thickness (IVth), and left ventricular posterior wall thickness (PWth).
Blood pressure, heart rate (HR), and body temperature (BT) were calculated as the means of respective values measured on 2 consecutive days prior to the conditioning regimen. The dissociation of HR and BT, called the HR-BT index, was calculated to evaluate 'relative tachycardia' as follows, assuming that the normal HR was 80 beats/min at 371C and increased by 20 beats/min with an increase in BT of 11C:
The mean HR-BT calculated from values measured on 2 consecutive days was used for the analysis.
The cumulative dose of anthracyclines was calculated as the equivalent dose of native doxorubicin, assuming that the cardiac toxicity at an equal dose is 0.5, 0.8, 3.4, 0.6, 1.6, and 0.1 for daunorubicin, pirarubicin, mitoxantrone, ) groups. Other potential confounding factors considered in the analysis included the history of irradiation involving the heart, presence or absence of anthracycline administration within 60 days before transplantation, and pre-transplant serum ferritin levels.
Evaluation of regimen-related cardiac toxicity
Regimen-related cardiac toxicity was graded according to Bearman grade. 2 Only cardiac complications that developed within 28 days after transplantation were considered regimen-related cardiac toxicity. Grade III-IV cardiac complications were defined to be severe.
Statistical analysis
For univariate analyses, continuous variables in the two groups were compared using the unpaired t-test or the Mann-Whitney U test, whereas categorical variables were compared using the w 2 test or Fisher's exact test. Factors associated with at least borderline significance (Po0.10) on univariate analysis were subjected to a multivariate analysis using backward stepwise logistic regression. P values of less than 0.05 were considered statistically significant.
Results
Severe cardiac complications after transplantation
Eight patients (4.9%) developed grade III-IV cardiac complications within 28 days after transplantation ( Table 1 ). Characteristics of the eight patients are shown in Table 2 . Manifestation of cardiac complications was mainly pulmonary congestion in five (patients 1, 2, 3, 7, and 8), while two had severe hypotension (patients 4 and 5). All had primary cardiac dysfunction, not secondary to other causes. Five developed cardiac toxicity during the preparative regimen and three of them died prior to hematopoietic stem cell transplantation. The remaining three patients developed cardiac toxicity 5, 6, and 11 days after transplantation, respectively. Seven died of cardiac causes a median of 3 days (range 0-45 days) after the onset of cardiac complications.
Risk factors for severe cardiac complications
The relationships between possible confounding factors and the development of severe cardiac complications are shown in Table 1 . Patient age, sex, and disease status were not associated with cardiac complications. None of the patients who developed cardiac complications had a history of cardiac disease before transplantation, while 12 of 153 patients who did not develop such complications had a prior history of cardiac disease (0% vs 8.4%, P40.99), including angina pectoris in two, arrhythmia in six, congestive heart failure in one, leukemic infiltration of the heart in two, and surgery for tetralogy of Fallot in one. Ten patients had diabetes mellitus, five had hypertension, and one had hyperlipidemia before transplantation, but none of them developed cardiac complications after transplantation. As for prior treatments, both the cumulative dose of anthracyclines and the use of anthracyclines within 60 days before transplantation affected the incidence of severe cardiac complications (P ¼ 0.0091 and 0.011, respectively; Figure 1 ).
There was no difference in the ECG findings, including QTc interval and QTc dispersion, between those who developed severe cardiac complications and those who did 38/F AML CR2 408 63 CY 120 mg/kg day 11 Severe CHF, (III), alive on day 686 fTBI 12 Gy/6 fr not. Furthermore, no difference was observed in the UCG findings, including EF and the E/A ratio, between the two groups. Impaired EF was more frequently observed in patients who developed severe cardiac complications, but the difference was not statistically significant (25% vs 11.2%, P ¼ 0.25). Heart rate and systolic blood pressure before transplantation were not correlated with the incidence of severe cardiac complications. However, a high HR-BT index, which reflected 'relative tachycardia', was associated with a higher incidence of cardiac complications (37.5% vs 7.2%, P ¼ 0.024).
The use of high-dose cyclophosphamide or ifosfamide was less frequent in patients who developed severe cardiac complications. This may have been because high-dose cyclophosphamide tended to be avoided in patients who were considered to be at higher risk for severe cardiac complications. The use of TBI did not affect the incidence of cardiac complications (P40.99).
By multivariate analysis, the cumulative dose of anthracyclines was identified as the only independent significant risk factor for severe cardiac complications, with an odds ratio of 4.33 (95% CI 1.48-12.7, P ¼ 0.0075) for changes between categories.
Discussion
Cardiac toxicity due to the conditioning regimen is a wellrecognized complication after hematopoietic stem cell transplantation. 2, 3, 9 The incidence of severe cardiac complications was 4.9% in this series, which is consistent with the values in previous reports (0.9%-26%). [1] [2] [3] [4] [5] [6] [7] [8] [9] We found that the cumulative dose of anthracyclines correlated independently with the development of grade III-IV cardiac complications. Five of the 29 patients (17.2%) who had received more than 400 mg/m 2 of anthracyclines developed severe cardiac complications. Furthermore, among this population, four of the 12 patients (33%) who had received anthracyclines within 60 days before transplantation developed severe cardiac complications, whereas these were seen in only one of 14 patients (7.1%) who had not received anthracyclines within 60 days, although this difference was not statistically significant (P ¼ 0.15).
The predictive value of pre-transplant cardiac evaluation has been inconsistent among studies. Braverman et al and Fujimaki et al showed that a reduced pre-transplant EF could be a predictive factor, 3,5 while Hertenstein et al showed that the incidence of life-threatening cardiac toxicity was not significantly increased in patients with reduced EF. 9 In this study, the incidence of severe cardiac toxicity was higher in the reduced EF (o55%) group, but this difference was not statistically significant (11.1% vs 4.5%, P ¼ 0.25). It is possible that the number of patients was too small to detect the difference; the statistical power of this study to detect the difference was only 15%. In addition, we tended to use less toxic regimens for patients with a reduced pre-transplant EF. This might also explain why a high-dose cyclophosphamide regimen was used less frequently in patients who developed severe cardiac complications.
In this study, we closely analyzed the correlation between severe cardiac complications and variables obtained by ECG or UCG, but none were useful for predicting cardiac complications after transplantation, although the usefulness of EF should not be excluded. On the other hand, relative tachycardia as shown by a high HR-BT index may reflect reduced cardiac reserve. In fact, a high HR-BT was associated with a higher incidence of severe cardiac complications on univariate analysis. Although this was not confirmed by multivariate analysis, it may be worthwhile to further evaluate the impact of this variable, since the HR-BT index can be determined easily without any cost. As another marker for cardiac reserve, Zangari et al showed that the increment of EF during excise was useful to predict overall peritransplant mortality, suggesting that pre-transplant cardiac reserve may be important in predicting transplant outcome. 14 In conclusion, patients who had received a high cumulative dose of anthracyclines, particularly more than 400 mg/m 2 , were at the highest risk for severe cardiac complications. Clinical interventions to prevent cardiac toxicity, such as the use of reduced-intensity conditioning or angiotensin-converting enzyme inhibitor as a cardioprotectant, should be evaluated in such patients. 15 Also, the administration of anthracyclines should be avoided within 2 months before transplantation. Risk factors for cardiac complications after transplantation M Sakata-Yanagimoto et al
